Latest Ocera Therapeutics Inc (OCRX) Headlines
3 Stocks Rising on Big Volume
at The Street - Thu Mar 06, 5:00AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Ocera Therapeutics to Announce Fourth Quarter and Year End Financial Results
GlobeNewswire - Mon Mar 03, 11:02PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter financial results on March 13, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
Ocera Therapeutics to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the Cowen Health Care Conference. Ocera's presentation is scheduled for Wednesday, March 5, 2014 at 8:00 AM ET.
5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.
Why Ocera (OCRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 7:37AM CST
Ocera could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
Nasdaq stocks posting largest percentage decreases
AP - Wed Jan 22, 12:47PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Ocera Therapeutics enrols first patient in Phase IIb Study of OCR-002 for treatment of acute hepatic encephalopathy
M2 - Thu Jan 09, 5:35AM CST
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Wednesday the admission of the first patient in its multi-centre Phase 2b study, the 'STOP-HE' or OCR002-HE209 trial.
Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy
GlobeNewswire - Wed Jan 08, 2:59PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced enrollment of the first patient in its multi-center Phase 2b study, the "STOP-HE" or OCR002-HE209 trial. This study is evaluating the efficacy, safety and pharmacokinetics of OCR-002, or ornithine phenylacetate, in hospitalized patients with liver cirrhosis and an acute episode of hepatic encephalopathy (HE). HE is a serious complication of liver failure and decompensated cirrhosis in the setting of chronic liver disease, where elevation of ammonia concentration in the blood and brain can lead to deterioration of neurocognitive function, ranging from subtle abnormalities to frank (overt) disorientation, stupor, coma and death. OCR-002 is a novel molecule, an ammonia scavenger which is intended to rapidly reduce the concentration of ammonia in the blood when administered as a continuous intravenous infusion. OCR-002 has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant HE in patients with acute liver failure or acute on chronic liver disease.
Ocera Therapeutics Announces Election of Wendell Wierenga to Board
GlobeNewswire - Tue Dec 24, 12:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that Wendell Wierenga, Ph.D., has joined its board of directors.
Ocera Therapeutics and the Roche Group Enter Into Technology Transfer and License Agreement
GlobeNewswire - Tue Dec 17, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH(TM)) discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH(TM) technology, and grant a license to Genentech and Roche under Ocera's related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4 million.
Ocera Therapeutics Announces Staffing Transition
GlobeNewswire - Wed Dec 11, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that David S. Moore, its chief business officer, will be leaving Ocera to pursue other opportunities. Mr. Moore was a former member of the management team at Tranzyme and continued his employment with Ocera following the merger of Ocera and Tranzyme, which closed in July 2013. "We are grateful to David for his leadership in overseeing several aspects of our post-merger integration and streamlining," said Linda Grais, M.D., chief executive officer of Ocera. "We wish him the best in his future endeavors."
Ocera Therapeutics to Present at Piper Jaffrey Healthcare Conference
GlobeNewswire - Tue Nov 26, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, plans to present at the 25 Annual Piper Jaffrey Healthcare Conference taking place at the New York Palace Hotel in New York City. Ocera's presentation is scheduled for Tuesday, December 3, 2013 at 04:10 PM ET. A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com.
Ocera Reports Third Quarter Business Update and Financial Results
GlobeNewswire - Wed Nov 13, 4:00PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today financial results for the three and nine months ended September 30, 2013.
Ocera Therapeutics Announces $28 Million Private Placement
GlobeNewswire - Wed Nov 06, 7:30AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today that it has obtained commitments to purchase common stock and warrants in a private placement. Gross proceeds from the private placement are expected to be $28 million before deducting fees and expenses. Ocera intends to use the net proceeds primarily to advance the clinical and nonclinical development of OCR-002, ornithine phenylacetate, for the treatment of hepatic encephalopathy. Ocera is planning to enroll patients in a Phase 2b study of the IV form of OCR-002 later this year, and to begin work on the oral form of OCR-002 in 2014.
Gastric Motility Disorder - Pipeline Review, H2 2013
M2 - Wed Nov 06, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/txxs36/gastric_motility) has announced the addition of the "Gastric Motility Disorder - Pipeline Review, H2 2013" report to their offering. 'Gastric Motility Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastric Motility Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Motility Disorder. The research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Scope - A snapshot of the global therapeutic scenario for Gastric Motility Disorder. - A review of the Gastric Motility Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gastric Motility Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Gastric Motility Disorder Overview Therapeutics Development An Overview of Pipeline Products for Gastric Motility Disorder Gastric Motility Disorder Therapeutics under Development by Companies Gastric Motility Disorder Therapeutics - Products under Development by Companies Companies Involved in Gastric Motility Disorder Therapeutics Development Gastric Motility Disorder - Therapeutics Assessment Drug Profiles - TZP-102 - velusetrag - ipamorelin - TD-8954 - Drug For Bowel Motility Disorders Featured News & Press Releases Appendix Companies Mentioned - Concert Pharmaceuticals, Inc. - Helsinn Healthcare S.A. - Ocera Therapeutics, Inc. - Theravance, Inc. For more information visit http://www.researchandmarkets.com/research/tx...c_motility
Neos Therapeutics, Inc. Announces the Appointment of Vipin K. Garg, Ph.D. as Chief Executive Officer and Board Director
Business Wire - Tue Oct 22, 10:00AM CDT
Neos Therapeutics, Inc. (Neos), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a pipeline of innovative controlled release (CR) products, announced today the appointment of Vipin K. Garg, Ph.D. to the role of Chief Executive Officer, effective immediately. Dr. Garg succeeds Neos Interim Chief Executive Officer, Alan Heller, who will continue serving as Chairman of the Neos Board of Directors. Dr. Garg will also serve as a member of the Neos Board of Directors.
Ocera Announces Post-Merger Closure of Quebec Research Site
GlobeNewswire - Tue Sep 17, 3:21PM CDT
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focusing on acute and chronic orphan liver diseases, today announced a restructuring plan involving the closure of operations in its Sherbrooke, Quebec facility effective November 11, 2013. The Sherbrooke facility housed 17 employees and research operations leveraging the Company's proprietary chemistry technology platform, MATCH (Macrocyclic Template Chemistry), used to develop novel pre-clinical and clinical stage product candidates. Ocera will retain full rights to this technology.
Ocera Therapeutics names Jeryl L. Hilleman as CFO and schedules conference for 12 September 2013
M2 - Tue Sep 03, 6:06AM CDT
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) reported on Tuesday the appointment of Jeryl L. Hilleman as its chief financial officer.
Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer
GlobeNewswire - Tue Sep 03, 4:10AM CDT
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Jeryl L. Hilleman has been appointed chief financial officer effective September 3, 2013. Ms. Hilleman will replace Dana McGowan who will continue with the company during a transition period in which the company plans to move its headquarters to Northern California.
3 Stocks Rising on Big Volume
at The Street - Thu Mar 06, 5:00AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Ocera Therapeutics to Announce Fourth Quarter and Year End Financial Results
GlobeNewswire - Mon Mar 03, 11:02PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter financial results on March 13, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
Ocera Therapeutics to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the Cowen Health Care Conference. Ocera's presentation is scheduled for Wednesday, March 5, 2014 at 8:00 AM ET.
5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.
Why Ocera (OCRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 7:37AM CST
Ocera could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
Nasdaq stocks posting largest percentage decreases
AP - Wed Jan 22, 12:47PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Ocera Therapeutics enrols first patient in Phase IIb Study of OCR-002 for treatment of acute hepatic encephalopathy
M2 - Thu Jan 09, 5:35AM CST
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Wednesday the admission of the first patient in its multi-centre Phase 2b study, the 'STOP-HE' or OCR002-HE209 trial.
Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy
GlobeNewswire - Wed Jan 08, 2:59PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced enrollment of the first patient in its multi-center Phase 2b study, the "STOP-HE" or OCR002-HE209 trial. This study is evaluating the efficacy, safety and pharmacokinetics of OCR-002, or ornithine phenylacetate, in hospitalized patients with liver cirrhosis and an acute episode of hepatic encephalopathy (HE). HE is a serious complication of liver failure and decompensated cirrhosis in the setting of chronic liver disease, where elevation of ammonia concentration in the blood and brain can lead to deterioration of neurocognitive function, ranging from subtle abnormalities to frank (overt) disorientation, stupor, coma and death. OCR-002 is a novel molecule, an ammonia scavenger which is intended to rapidly reduce the concentration of ammonia in the blood when administered as a continuous intravenous infusion. OCR-002 has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant HE in patients with acute liver failure or acute on chronic liver disease.
Ocera Therapeutics Announces Election of Wendell Wierenga to Board
GlobeNewswire - Tue Dec 24, 12:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that Wendell Wierenga, Ph.D., has joined its board of directors.
Ocera Therapeutics and the Roche Group Enter Into Technology Transfer and License Agreement
GlobeNewswire - Tue Dec 17, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH(TM)) discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH(TM) technology, and grant a license to Genentech and Roche under Ocera's related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4 million.
Ocera Therapeutics Announces Staffing Transition
GlobeNewswire - Wed Dec 11, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that David S. Moore, its chief business officer, will be leaving Ocera to pursue other opportunities. Mr. Moore was a former member of the management team at Tranzyme and continued his employment with Ocera following the merger of Ocera and Tranzyme, which closed in July 2013. "We are grateful to David for his leadership in overseeing several aspects of our post-merger integration and streamlining," said Linda Grais, M.D., chief executive officer of Ocera. "We wish him the best in his future endeavors."
Ocera Therapeutics to Present at Piper Jaffrey Healthcare Conference
GlobeNewswire - Tue Nov 26, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, plans to present at the 25 Annual Piper Jaffrey Healthcare Conference taking place at the New York Palace Hotel in New York City. Ocera's presentation is scheduled for Tuesday, December 3, 2013 at 04:10 PM ET. A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com.
Ocera Reports Third Quarter Business Update and Financial Results
GlobeNewswire - Wed Nov 13, 4:00PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today financial results for the three and nine months ended September 30, 2013.
Ocera Therapeutics Announces $28 Million Private Placement
GlobeNewswire - Wed Nov 06, 7:30AM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today that it has obtained commitments to purchase common stock and warrants in a private placement. Gross proceeds from the private placement are expected to be $28 million before deducting fees and expenses. Ocera intends to use the net proceeds primarily to advance the clinical and nonclinical development of OCR-002, ornithine phenylacetate, for the treatment of hepatic encephalopathy. Ocera is planning to enroll patients in a Phase 2b study of the IV form of OCR-002 later this year, and to begin work on the oral form of OCR-002 in 2014.
Gastric Motility Disorder - Pipeline Review, H2 2013
M2 - Wed Nov 06, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/txxs36/gastric_motility) has announced the addition of the "Gastric Motility Disorder - Pipeline Review, H2 2013" report to their offering. 'Gastric Motility Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastric Motility Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Motility Disorder. The research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Scope - A snapshot of the global therapeutic scenario for Gastric Motility Disorder. - A review of the Gastric Motility Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gastric Motility Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Gastric Motility Disorder Overview Therapeutics Development An Overview of Pipeline Products for Gastric Motility Disorder Gastric Motility Disorder Therapeutics under Development by Companies Gastric Motility Disorder Therapeutics - Products under Development by Companies Companies Involved in Gastric Motility Disorder Therapeutics Development Gastric Motility Disorder - Therapeutics Assessment Drug Profiles - TZP-102 - velusetrag - ipamorelin - TD-8954 - Drug For Bowel Motility Disorders Featured News & Press Releases Appendix Companies Mentioned - Concert Pharmaceuticals, Inc. - Helsinn Healthcare S.A. - Ocera Therapeutics, Inc. - Theravance, Inc. For more information visit http://www.researchandmarkets.com/research/tx...c_motility
Neos Therapeutics, Inc. Announces the Appointment of Vipin K. Garg, Ph.D. as Chief Executive Officer and Board Director
Business Wire - Tue Oct 22, 10:00AM CDT
Neos Therapeutics, Inc. (Neos), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a pipeline of innovative controlled release (CR) products, announced today the appointment of Vipin K. Garg, Ph.D. to the role of Chief Executive Officer, effective immediately. Dr. Garg succeeds Neos Interim Chief Executive Officer, Alan Heller, who will continue serving as Chairman of the Neos Board of Directors. Dr. Garg will also serve as a member of the Neos Board of Directors.
Ocera Announces Post-Merger Closure of Quebec Research Site
GlobeNewswire - Tue Sep 17, 3:21PM CDT
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focusing on acute and chronic orphan liver diseases, today announced a restructuring plan involving the closure of operations in its Sherbrooke, Quebec facility effective November 11, 2013. The Sherbrooke facility housed 17 employees and research operations leveraging the Company's proprietary chemistry technology platform, MATCH (Macrocyclic Template Chemistry), used to develop novel pre-clinical and clinical stage product candidates. Ocera will retain full rights to this technology.
Ocera Therapeutics names Jeryl L. Hilleman as CFO and schedules conference for 12 September 2013
M2 - Tue Sep 03, 6:06AM CDT
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) reported on Tuesday the appointment of Jeryl L. Hilleman as its chief financial officer.
Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer
GlobeNewswire - Tue Sep 03, 4:10AM CDT
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Jeryl L. Hilleman has been appointed chief financial officer effective September 3, 2013. Ms. Hilleman will replace Dana McGowan who will continue with the company during a transition period in which the company plans to move its headquarters to Northern California.
